爵士制药(Jazz Pharmaceuticals)近日宣布，美国食品药品监督管理局(FDA)已正式接受并授予优先审评资格，针对其创新药物Ziihera®（扎尼达坦单抗）联合疗法用于一线治疗HER2阳性局部晚期或转移性胃食管腺癌(GEA)的补充生物制剂许可申请(sBLA)。这一重要监管进展将显著加速该疗法在晚期胃癌领域的商业化进程。
FDA的优先审评资格通常授予那些在治疗严重疾病方面展现显著优势的创新疗法，审评周期将从标准的10个月缩短至6个月。此次突破性进展基于Ziihera®在临床研究中展现出的卓越疗效数据，该药物作为新一代HER2靶向疗法，有望为晚期胃癌患者提供新的治疗选择。
此次监管里程碑标志着爵士制药在肿瘤治疗领域的重要突破，也体现了公司持续推动创新疗法惠及患者的坚定承诺。随着审评进程的推进，Ziihera®有望成为HER2阳性胃癌治疗领域的重要补充，为患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.